Cinctive Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Cinctive Capital Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,388	Closed	-$996K	–	396
2022 Q3	$996K	Sell	2,388 -1,892	-44%	-$943K	0.04%	343
2022 Q2	$2.12M	Sell	4,280 -27,370	-86%	-$14.3M	0.09%	307
2022 Q1	$17.8M	Buy	+31,650	New	+$19.1M	0.66%	25
2021 Q1	–	Sell	-6,150	Closed	-$3.58M	–	412
2020 Q4	$3.58M	Sell	6,150 -13,191	-68%	-$7.51M	0.29%	146
2020 Q3	$9.97M	Buy	19,341 +4,929	+34%	+$2.5M	0.87%	16
2020 Q2	$6.51M	Buy	14,412 +2,276	+19%	+$1M	0.75%	23
2020 Q1	$4.25M	Sell	12,136 -5,364	-31%	-$1.97M	0.95%	27
2019 Q4	$6.48M	Buy	+17,500	New	+$6.17M	0.68%	44

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Cinctive Capital Management's BIO Position: Q4 2022 in Review

Cinctive Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2022, closing a stake of 2,388 shares — an estimated $996K sold.

Cinctive Capital Management first reported a position in BIO in Q4 2019 and held it in 8 quarters. The position peaked at $17.8M in Q1 2022. 470 funds tracked by Wall St. Rank hold BIO as of Q4 2022.

Cinctive Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q4 2022 after selling out during the quarter.
Cinctive Capital Management sold 2,388 Bio-Rad Laboratories Class A shares in Q4 2022, an estimated $996K.
Cinctive Capital Management first reported a position in Bio-Rad Laboratories Class A in Q4 2019 and held it in 8 quarters.
Cinctive Capital Management's Bio-Rad Laboratories Class A position peaked at $17.8M in Q1 2022.
470 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2022.

Based on Cinctive Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.